Regulation & Industry
13 October 2026 Potential reforms to post-employment restrictions and contractual notice periods could make it harder for brand owners to protect trade secrets and manage staff departures, prompting questions about how businesses can safeguard their interests.
30 September 2026
18 September 2026
17 September 2026
More News
11 September 2026 For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.
4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.
4 September 2026 Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.
27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.
25 August 2026 While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.
24 August 2026 Labour MP for Stockton North takes up a new role as Minister for Science, Innovation and Investment within Andy Burnham’s government.
Latest Features
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox